Elicio Therapeutics, Inc.

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Dealmaking will continue to pick up in 2023, but don’t expect mega-mergers. That’s the message from many industry-watchers, chastened by a largely forgettable 2022 that failed to deliver the expected

After attempting to get through the initial public offering window without success during 2021-2022, Elicio Therapeutics is taking its lymph node-directed cancer vaccine technology public through a

Third Harmonic Bio launched an initial public offering on 14 September that marked the first IPO in the US by a biopharmaceutical company in four months to raise more than $100m. In fact, the last th